TY - JOUR
AU - J. B. Jarrett
AU - J. Bratberg
AU - A. L. Burns
AU - G. Cochran
AU - B. A. DiPaula
AU - Legreid Dopp
AU - A. Elmes
AU - T. C. Green
AU - L. G. Hill
AU - F. Homsted
AU - S. L. Hsia
AU - M. L. Matthews
AU - U. E. Ghitza
AU - L. T. Wu
AU - G. Bart
A1 - 
AB - In the last decade, the U.S. opioid overdose crisis has magnified, particularly since the introduction of synthetic opioids, including fentanyl. Despite the benefits of medications for opioid use disorder (MOUD), only about a fifth of people with opioid use disorder (OUD) in the U.S. receive MOUD. The ubiquity of pharmacists, along with their extensive education and training, represents great potential for expansion of MOUD services, particularly in community pharmacies. The National Institute on Drug Abuse's National Drug Abuse Treatment Clinical Trials Network (NIDA CTN) convened a working group to develop a research agenda to expand OUD treatment in the community pharmacy sector to support improved access to MOUD and patient outcomes. Identified settings for research include independent and chain pharmacies and co-located pharmacies within primary care settings. Specific topics for research included adaptation of pharmacy infrastructure for clinical service provision, strategies for interprofessional collaboration including health service models, drug policy and regulation, pharmacist education about OUD and OUD treatment, including didactic, experiential, and interprofessional curricula, and educational interventions to reduce stigma towards this patient population. Together, expanding these research areas can bring effective MOUD to where it is most needed.
AD - Department of Pharmacy Practice, College of Pharmacy, University of Illinois Chicago, Chicago, USA.; Department of Pharmacy Practice and Clinical Research, College of Pharmacy, University of Rhode Island, Kingston, RI, USA.; American Pharmacists Association, Washington, DC, USA (retired).; Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, UT, USA.; Department of Practice, Sciences, and Health Outcomes Research, School of Pharmacy, University of Maryland Baltimore, Baltimore, MD, USA.; American Society of Health-System Pharmacists, Washington, DC, USA.; COBER on Opioids and Overdose at Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI, USA.; Opioid Policy Research Collaborative, The Heller School for Social Policy and Management, Brandeis University, Waltham, MA, USA.; The University of Texas at Austin, College of Pharmacy, Austin, TX, USA.; FQHC 340B Compliance, Inc., Lebanon, TN, USA.; Department of Clinical Pharmacy, San Francisco School of Pharmacy, University of California, San Francisco, CA, USA.; Department of Pharmacy Practice, School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA.; National Institute on Drug Abuse (NIDA), Center for the Clinical Trials Network (CCTN), Bethesda, MD, USA.; Duke University School of Medicine, Durham, NC, USA.; Department of Medicine, Hennepin Healthcare, Minneapolis, MN, USA.
AN - 37902032
BT - Subst Abus
C5 - Opioids & Substance Use; Education & Workforce
CP - 4
DA - Oct
DO - 10.1177/08897077231203849
DP - NLM
ET - 20231030
IS - 4
JF - Subst Abus
LA - eng
N2 - In the last decade, the U.S. opioid overdose crisis has magnified, particularly since the introduction of synthetic opioids, including fentanyl. Despite the benefits of medications for opioid use disorder (MOUD), only about a fifth of people with opioid use disorder (OUD) in the U.S. receive MOUD. The ubiquity of pharmacists, along with their extensive education and training, represents great potential for expansion of MOUD services, particularly in community pharmacies. The National Institute on Drug Abuse's National Drug Abuse Treatment Clinical Trials Network (NIDA CTN) convened a working group to develop a research agenda to expand OUD treatment in the community pharmacy sector to support improved access to MOUD and patient outcomes. Identified settings for research include independent and chain pharmacies and co-located pharmacies within primary care settings. Specific topics for research included adaptation of pharmacy infrastructure for clinical service provision, strategies for interprofessional collaboration including health service models, drug policy and regulation, pharmacist education about OUD and OUD treatment, including didactic, experiential, and interprofessional curricula, and educational interventions to reduce stigma towards this patient population. Together, expanding these research areas can bring effective MOUD to where it is most needed.
PY - 2023
SN - 0889-7077 (Print); 0889-7077
SP - 264
EP - 276+
ST - Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy
T1 - Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy
T2 - Subst Abus
TI - Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy
U1 - Opioids & Substance Use; Education & Workforce
U3 - 10.1177/08897077231203849
VL - 44
VO - 0889-7077 (Print); 0889-7077
Y1 - 2023
ER -